Results 131 to 140 of about 7,735 (207)

Overcoming Limits of Immunoconjugates [PDF]

Nature Biotechnology, 1991
openaire   +1 more source

PD-1/PD-L1 Cancer Immunotherapeutics Reshape Tumor Microenvironment - Clinical Evidence and Molecular Mechanisms for AI-based Precision Medicine. [PDF]

Clin Rev Allergy Immunol
Lin YY, Ding JL, Shen HT, Lin YM, Adhidjaja EC, Chang SC.   +5 more
europepmc   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

[²²⁵Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer. [PDF]

Breast Cancer Res
Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H.   +9 more
europepmc   +1 more source

Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloads. [PDF]

Med
Nikanjam M, Kurzrock R.
europepmc   +1 more source

Evaluating Radiotheranostic Targets for Endometrial Cancer. [PDF]

J Nucl Med
Sebastiano J, McGlone SA, Samuels ZV, Grimaldi C, Stoddard A, Galka S, Colaco E, Zeglis BM.   +7 more
europepmc   +1 more source

FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation? [PDF]

Breast
Orlandi A.
europepmc   +1 more source

Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer. [PDF]

ACS Pharmacol Transl Sci
Rodriguez C, Sarrett SM, Sebastiano J, Delaney S, McGlone SA, Hosny MM, Thau S, Bournazos S, Zeglis BM.   +8 more
europepmc   +1 more source

Polatuzumab vedotin plus rituximab with chemotherapy in newly diagnosed pediatric stage IV Burkitt lymphoma: case report highlighting early complete remission. [PDF]

Front Immunol
Sun Y, Deng M, Zhang C, Chen Y, Zhang Y, Zuo W.   +5 more
europepmc   +1 more source

Xoma Immunoconjugate Gets Early OK [PDF]

Nature Biotechnology, 1991
openaire   +1 more source